FINNENCE▪
00:00:00 UTCSYS ONLINE
FINNENCE ▪ THE WIRE FILE

THE WIRE · № 69670

News▼ Bearish

AVBP SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving ArriVent BioPharma

EXHIBIT · mmx.prnewswire.com
KINDNews
DIRECTION▼ Bearish
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN2026-10-07 18:20 UTC
LAST UPDATE2026-10-07 18:20 UTC
STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

A Phase 3 miss and 56.7% premarket drop plus securities investigation raise single-name biotech risk and legal overhang.

Clinical miss plus investigation pressures the stock
CATALYST TO WATCH

Details of the securities investigation

MAIN RISK

Further downside if claims gain traction

FULL DISPATCH

AVBP was down 56.7% before the opening bell and traded as low as $12.09 after ArriVent disclosed that its Phase 3 FURVENT trial of firmonertinib missed its primary endpoint. An investigation into potential securities law violations is underway. NEW YORK, Oct. 7, 2026 /PRNewswire/ --...

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

AFFECTEDHealthcare

04 RECEIPTS

THE SOURCE RECORD.

1 SOURCES CONFIRMED
№ 01prnewswireprnewswire.com · PRIMARY2026-10-07 18:20 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.